Simultaneous Mutation Detection in 90 Retinal Disease Genes in Multiple Patients Using a Custom-designed 300-kb Retinal Resequencing Chip

详细信息    查看全文

• 作者：Judith C. Booij MD ; PhD¹ ; Arne Bakker BSc¹ ; Jamilia Kulumbetova MD ; PhD¹ ; Youssef Moutaoukil BSc¹ ; Bert Smeets PhD² ; Joke Verheij MD ; PhD³ ; Hester Y. Kroes MD ; PhD⁴ ; Caroline C.W. Klaver MD ; PhD⁵ ; Mary van Schooneveld MD ; PhD¹ ; Arthur A.B. Bergen PhD¹ ; ⁶ ; ⁷ ; ^{a.bergen@nin.knaw.nl} ; Ralph J. Florijn PhD¹
• 刊名：Ophthalmology
• 出版年：2011
• 出版时间：January 2011
• 年：2011
• 卷：118
• 期：1
• 页码：160-167.e3
• 全文大小：1491 K

文摘

Purpose

To develop a high-throughput, cost-effective diagnostic strategy for the identification of known and new mutations in 90 retinal disease genes.

Design

Evidence-based study.

Participants

Sixty patients with a variety of retinal disorders, including Leber's congenital amaurosis, ocular albinism, pseudoxanthoma elasticum, retinitis pigmentosa, and Stargardt's disease.

Methods

We designed a custom 300-kb resequencing chip. Polymerase chain reaction (PCR) amplification, DNA fragmentation, and chip hybridization were performed according to Affymetrix recommendations. Hybridization signals were analyzed using Sequence pilot module seq-C mutation detection software (2009). This resequencing approach was validated by Sanger sequence technology.

Main Outcome Measures

Disease-causing sequence changes.

Results

We developed a retinal resequencing chip that covers all exons of 90 retinal disease genes. We developed and tested multiplex primer sets for 1445 amplicons representing the genes included on the chip. We validated our approach by screening 87 exons from 25 retinal disease genes containing 87 known sequence changes previously identified in our patient group using Sanger sequencing. Call rates for successfully hybridized amplicons were 98 % to 100 % . Of the known single nucleotide changes, 99 % could be detected on the chip. As expected, deletions could not be detected reliably.

Conclusions

We designed a custom resequencing chip that can detect known and new sequence changes in 90 retinal disease genes using a new high-throughput strategy with a high sensitivity and specificity for one tenth of the cost of conventional direct sequencing. The developed amplification strategy allows for the pooling of multiple patients with non-overlapping phenotypes, enabling many patients to be analyzed simultaneously in a fast and cost-effective manner.

Financial Disclosure(s)

The author(s) have no proprietary or commercial interest in any materials discussed in this article.